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A POSITIVE antidonor T-cell Iymphocytotoxic cross-
match (X-M) has been shown to have a deleterious 
effect on graft survival after solid organ transplantation.I-3 
This is the first report to address the impact of preformed 
antidonor IgG Iymphocytotoxic antibodies on intestinal 
allograft rejection and survival. 
MATERIALS AND METHODS 
Over a 9-year period, 124 consecutive patients received a total of 
130 intestinal allografts at our center: 51 isolated intestines and 79 
composite visceral grafts (62 liver/intestine and 17 multivisceral). 
Of these, 51 % were male and 58% were children. All donors were 
cadaveric and ABO identical. The HLA match was random and no 
attempts were made to immunomodulate the graft. The baseline 
immunosuppression was tacrolimus and steroids. Daclizumab was 
used as an induction therapy for the last 17 patients and OKTI was 
utilized to treat steroid-resistant rejection. In 27 allografts (4 
positive X-M. 23 negative X·M), a single dose (3 to 5 x 108 cells!kg 
body weight) of unmodified donor bone marrow cells were infused 
intravenously within 24 hours after graft implantation. The X-M 
test was performed in all patients by obtaining recipient sera 
immediately before transplantation that tested for cytotoxic anti-
body activity against donor T lymphocytes as previously described." 
To shorten the cold-ischemia time, the recipient operation was 
often started before the results of the X-M were available. The 
X-M was positive with dithiothreitol (DTI) in 23 (18%) grafts. All 
were primary grafts with 7 (30%) isolated intestines and 16 (70%) 
composite visceral grafts that contained liver. Twelve were children 
and 11 were adults with a relative predominance of adult females 
(39%). The clinical features of both positive and negative X-M 
recipients were similar, including number of previous abdominal 
operations, operative time, cold-ischemia time. donor/recipient 
CMV status, and median follow-up period. The donor and recipi-
ent operations as well as the perioperative management strategy 
were the same in both groups as described elsewhere.4•s The 
Kaplan-Meier method was used to calculate survival rates. Chi-
square and standard t tests were used for statistical analysis. 
RESULTS 
With a mean follow-up of 27 months, 10 (2 isolated 
intestine, 8 composite visceral) of the 23 positive X-M 
allografts were lost, with an overall survival of 57%. The 
causes of the 10 graft (patient) losses were opportunistic 
infections in 5 (PTLD = 3, CMV = 1. fungal sepsis = 1), 
rejection in 3 (acute = 2, chronic = 1), and dissection of the 
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ascending thoracic aorta in 1. The remaining graft (liver/ 
intestine) was transplanted across a high-Iymphocytotoxic 
antibody titer (1:512) to a black pediatric recipient who died 
of primary graft failure 4 days after transplantation. Hyper-
acute rejection could not be excluded in such a case despite 
failure of the conducted immunohistochemical and patho-
logic studies to confirm the diagnosis. Using the negative 
X-M grafts as control. the presence of preformed lympho-
cytotoxic antibodies did not significantly affect the 5-year 
actuarial (Kaplan-Meier) patient and graft survival. 
Intestinal allograft rejection occurred in 91 % of the 
positive and 84% of the negative X-M (control) grafts. The 
mean (SD) number of rejection episodes per graft was also 
higher for the positive compared with the negative X-M 
grafts (5.4 :± 5 vs 4.0 :± 4) as was the need to use OKT3 
(43% vs 33%). Such differences between positive and 
negative X-M grafts were significantly higher among the 
isolated intestine cases, with a mean frequency of 7.3 :± 8 vs 
4.1 :± 4 and an OKT3 use of 86% vs 45% (P = .05). Within 
the positive X-M grafts, the mean number of intestinal 
rejection episodes per graft was significantly less for com-
posite visceral (4.5 :± 3) compared with isolated intestinal 
(7.1 :± 7) allografts. The need for OKT3 was also signifi-
cantly (P = .03) less, with an incidence of 27% and 75%, 
respectively. 
CMV disease developed with a higher incidence among 
the positive (58%) compared to the negative X-M (27%) 
group. However, PTLD occurred with equal frequency 
(22%) among both cohorts. None of the positive X-M 
recipients developed GVHD. 
DISCUSSION 
In this series, 18% of our intestinal recipients were harbor-
ing preformed antidonor IgG lymphocytotoxic antibodies. 
This relatively high rate, compared with other solid organ 
transplant recipients,I-3 could be attributed to the mUltiple 
abdominal operations that these patients received before 
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transplantation with the frequent need for multiple blood 
transfusion. 
Similar to other solid organ allografts. positive T-cell 
Iymphocytotoxic X-M increased the frequency and severity 
of intestinal rejection. Such a risk was significantly higher 
among patients who received intestine only. The simulta-
neously transplanted liver as part of a composite visceral 
allograft seemed to ameliorate the negative effect of the 
preformed antibodies and X-M reactivity. These data fur-
ther support our previous observation that the liver is 
significantly protective of concomitantly engrafted intes-
tine.s 
In conclusion, positive T-cell lymphocytotoxic X-M in-
creases the frequency and severity of rejection after intes-
tinal transplantation, particularly with isolated intestine. 
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Therefore. our current recommendation. until better immu-
nomodulation strategies can be established, is to avoid 
transplanting positive X-M allografts to patients who are 
not in urgent need of an isolated intestine. 
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